



RECEIVED
JUL 15 2002

TECH CENTER 1600/2000
JUL 15 2002

In re Application of: Ulrich SPECK et al

Serial No.: 09/446,328

Group Art Unit: 1619

Filed: 17 April 2000

Examiner: G. Hollinden

For: USE OF INTRAVENOUS CONTRAST MEDIA FOR PROJECTION MAMMOGRAPHY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents
Washington, D. C. 20231

I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed To: Commissioner of Patents and Trademarks, Washington, D.C. 20231 On: July 1, 2002
Name: CSPB/HM/EP
Signature: [Signature]
Date: July 1, 2002

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- Copies of materials listed but not attached were cited in parent application Serial No. _____; see 37 C.F.R. § 1.98(d).
- Copies of materials listed but not attached were cited in an International Search Report dated _____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed _____.

ADDITIONAL INFORMATION

[NONE?]

LANGUAGE

- All listed materials are in the English language; see 37 C.F.R. § 1.98.
- Non-English language references:
 - The reference(s): _____ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): _____, respectively.
 - (An) English-language translation(s) of the references: _____ is (are) provided.
 - A commercial English-language abstract of reference(s) _____ is (are) provided.
 - An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

FEES

- No fee is required for this Information Disclosure Statement because:
 - This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
 - This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
 - This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
 - This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- A fee is required for this Information Disclosure Statement:
 - This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
 - This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.


CERTIFICATION

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$180.00. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Csaba Henter, Reg. No. 50,908
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1653

Date: July 1, 2002

CH:jph

K:\Sch\1653\Information Disclosure Statement.doc